Preparing for Hurricane Otis: Steps to Stay Safe

Hurricane Otis, a potentially catastrophic storm, is currently heading towards Mexico, raising concerns for the safety and well-being of the residents in its path. As we closely monitor the situation, it is crucial for everyone to take necessary precautions and be prepared for the potential impact of this powerful hurricane.Here are some important steps to help you stay safe during

Derick Alison Derick Alison

Mid-Stage Win for Novel IgA Nephropathy Drug

PHILADELPHIA -- An investigational humanized IgG2 monoclonal antibody reduced proteinuria in adults with immunoglobulin A (IgA) nephropathy at high risk for disease progression despite standard treatments, a randomized phase II trial found. In a dose-dependant manner, intravenous sibeprenlimab led to significantly greater decreases in 24-hour urinary protein-to-creatinine ratio at 12 months compared with placebo, with geometric mean ratio reductions ranging

Derick Alison Derick Alison

Study: Fewer Kids in the ED Means More Missed Diagnoses

Emergency departments (EDs) that saw fewer kids were more likely to have potentially delayed diagnoses for serious acute conditions in that population, a large retrospective cohort study showed. For pediatric patients, the overall risk of possible delayed diagnosis -- having an ED discharge within the 7 days prior to diagnosis -- dropped by 26.7% (95% CI 22.5-30.7) for every two-fold

Derick Alison Derick Alison

Editor's Pick

clear sky
5° _ 3°
5 km/h

Follow US

Discover Categories


20 Articles


159 Articles

Washington Watch

36 Articles

Topical Treatment for Epidermolysis Bullosa Wins FDA Approval

The FDA approved birch triterpenes (Filsuvez) topical gel for the treatment of epidermolysis bullosa (EB), Chiesi Global Rare Diseases announced on Tuesday. The approval stipulates use for partial thickness wounds in adults and pediatric patients at least 6 months old with dystrophic and junctional EB (JEB). The topical gel is the first approved treatment specifically indicated for JEB, a rare, moderate-to-severe form of EB that causes blisters beginning in infancy. "The FDA's decision to approve Filsuvez provides those living with EB a safe and effective treatment option for the most prominent and difficult symptom of EB, open wounds that may not heal," said Brett Kopelan, executive director of debra of America, in the company statement. Support for the approval came from the international phase III randomized EASE trial comparing birch triterpenes gel with a control gel in 223 patients with EB, including 156 pediatric patients. The trial met the primary endpoint, showing that 41.3% of patients treated with the active gel achieved first complete target wound closure within 45 days, as compared with 28.9% of the control group (P=0.013). Adverse events occurred in a similar proportion of patients in both treatment groups, the most common of which were application site reactions. Most were grade 1/2 in severity. The birch triterpenes topical gel contains dry extract from two species of birch bark, according to the company statement. The bark contains naturally occurring triterpenes, including betulin, betulinic acid, erythrodiol, lupeol, and oleanolic acid. According to the product labeling, birch triterpenes gel should be applied to a wound surface at a thickness of 1 mm and covered by a wound dress until healed. The gel may also be applied directly to the dressing. It should not be rubbed into the wound. Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined MedPage Today in 2007. Follow Please enable JavaScript to view the comments powered by Disqus. Source link

Derick Alison Derick Alison

China Reports No ‘Unusual’ Pathogens Driving Pneumonia Cluster in Kids

Chinese health authorities told the World Health Organization (WHO) that a surge in respiratory illness among children in the northern part of the country is simply part of a continued

Derick Alison Derick Alison